Development · 30 Aug 2026

Uno Minda Limited's Nomination and Remuneration Committee approved the allotment of 3,64,806 equity shares of face value Rs. 2/- each on February 21, 2026, pursuant to exercise of options under Uno Minda Employees Stock Option Scheme 2019.

1 publisher has reported this development. Each act of reporting is below, cited.

The record

bseindia.com21 Feb 2026

A single act of reporting so far, corroborating sources join this record as they publish.

UNO Minda

₹1,111.00

▼ -5.04%

Close (EOD), as of 1 Oct 2026 · source

UNO Minda: results, dividends, orders, the full cited record →

More on UNO Minda

Dr Reddys Laboratories Ltd is quoting at Rs 1213, up 0.17% on the day as on 12:44 IST on the NSE.

24 Sep 2026 · 2 publishers

Uno Minda announced a series of strategic capacity expansion and plant consolidation projects across its key business verticals to strengthen its manufacturing footprint, boost capacities across key divisions, and cater to surging demand from leading Original Equipment Manufacturers (OEMs).

16 Sep 2026 · 3 publishers

Uno Minda plans to invest ₹1,415 crore across its business verticals to strengthen its manufacturing footprint and boost capacities.

15 Sep 2026 · 1 publisher

Uno Minda Ltd's board approved projects involving an estimated ₹1,415 crore in incremental capital expenditure across four facilities, and the issuance of up to ₹600 crore of non-convertible debentures and commercial papers with a revolving limit of up to ₹500 crore.

14 Sep 2026 · 1 publisher

Minda Corporation is targeting revenue of Rs 17,500 crore by FY30, representing more than threefold growth from Rs 5,056 crore in FY25, with growth driven by higher-value products, electric vehicles and automotive electronics.

31 Aug 2026 · 1 publisher

Every claim carries its citation

This page is the corroborated record of one development: what each credible source reported, linked and dated. We compile and cite; we do not opine.

New here? The reader's guide explains every page, plate by plate.

fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.